Kevin D'Amour's Insider Trades & SAST Disclosures
Kevin D'Amour's most recent trade in Eterna Therapeutics Inc was a trade of 17,573 Restricted Stock Units done . Disclosure was reported to the exchange on June 28, 2022.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Kevin D'Amour.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Eterna Therapeutics Inc | Kevin D'Amour | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2022 | 17,573 | 52,717 | - | - | Restricted Stock Units | |
| Eterna Therapeutics Inc | Kevin D'Amour | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2022 | 17,573 | 17,573 | - | - | Common Stock | |
| Eterna Therapeutics Inc | Kevin D'Amour | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.55 per share. | 28 Jun 2022 | 6,077 | 11,496 | - | 0.6 | 3,363 | Common Stock |
| Eterna Therapeutics Inc | Kevin D'Amour | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2022 | 138,400 | 138,400 | - | - | Stock Option (Right to buy) | |
| Eterna Therapeutics Inc | Kevin D'Amour | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2021 | 140,580 | 140,580 | - | - | Stock Option | |
| Eterna Therapeutics Inc | Kevin D'Amour | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2021 | 70,290 | 70,290 | - | - | Restricted Stock Unit |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges